Cardlytics (NASDAQ:CDLX) Receives New Coverage from Analysts at Northland Securities

Northland Securities initiated coverage on shares of Cardlytics (NASDAQ:CDLX) in a research report report published on Tuesday morning, MarketBeat Ratings reports. The brokerage issued an outperform rating and a $14.00 price objective on the stock.

Several other analysts have also recently issued reports on CDLX. Lake Street Capital upped their price objective on shares of Cardlytics from $13.00 to $18.00 and gave the company a buy rating in a research note on Friday, March 15th. Needham & Company LLC reaffirmed a buy rating and set a $12.00 price objective on shares of Cardlytics in a research note on Tuesday, June 11th. Finally, Craig Hallum dropped their price target on shares of Cardlytics from $18.00 to $12.00 and set a buy rating for the company in a research note on Thursday, May 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average price target of $13.00.

Cardlytics Stock Down 0.4 %

CDLX stock opened at $8.21 on Tuesday. The stock has a market capitalization of $400.24 million, a P/E ratio of -1.86 and a beta of 1.68. The firm has a 50-day simple moving average of $10.75 and a 200-day simple moving average of $9.58. The company has a quick ratio of 2.13, a current ratio of 2.13 and a debt-to-equity ratio of 1.30. Cardlytics has a 52 week low of $5.53 and a 52 week high of $20.52.

Cardlytics (NASDAQ:CDLX) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.35) earnings per share (EPS) for the quarter. Cardlytics had a negative net margin of 55.23% and a negative return on equity of 25.36%. The business had revenue of $67.61 million for the quarter.

Insider Activity

In other news, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $13.69, for a total value of $170,577.40. Following the transaction, the insider now directly owns 71,355 shares in the company, valued at approximately $976,849.95. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, major shareholder Clifford Sosin acquired 3,746 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were purchased at an average cost of $8.99 per share, for a total transaction of $33,676.54. Following the acquisition, the insider now owns 6,464,859 shares in the company, valued at approximately $58,119,082.41. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Nicholas Hollmeyer Lynton sold 12,460 shares of the company’s stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $13.69, for a total transaction of $170,577.40. Following the completion of the transaction, the insider now owns 71,355 shares in the company, valued at $976,849.95. The disclosure for this sale can be found here. Insiders sold a total of 79,435 shares of company stock valued at $828,269 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Cardlytics

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in Cardlytics by 2.7% during the 1st quarter. Vanguard Group Inc. now owns 2,211,595 shares of the company’s stock worth $32,046,000 after buying an additional 57,805 shares in the last quarter. Invesco Ltd. increased its position in shares of Cardlytics by 538.1% in the 3rd quarter. Invesco Ltd. now owns 803,241 shares of the company’s stock valued at $13,253,000 after purchasing an additional 677,354 shares during the last quarter. General Equity Holdings LP increased its position in shares of Cardlytics by 31.0% in the 4th quarter. General Equity Holdings LP now owns 624,058 shares of the company’s stock valued at $5,748,000 after purchasing an additional 147,843 shares during the last quarter. LPL Financial LLC increased its position in shares of Cardlytics by 27.5% in the 3rd quarter. LPL Financial LLC now owns 424,150 shares of the company’s stock valued at $6,998,000 after purchasing an additional 91,400 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Cardlytics by 12.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 283,086 shares of the company’s stock valued at $4,671,000 after purchasing an additional 32,228 shares during the last quarter. 68.10% of the stock is currently owned by institutional investors and hedge funds.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.